We then demonstrated the therapeutic efficacy of a novel ACMSD inhibitor in a dietary mouse model of MASLD/MASH, through the mitigation of DNA damage, and confirmed the translational relevance of ACMSD inhibition in human liver organoid (HLO) models of steatohepatitis. This evidence concerns the gene ACMSD and metabolic dysfunction-associated steatotic liver disease.